Experience with independent radiological review during a topotecan trial in ovarian cancer

Annals of Oncology

Volumn 8, Issue 5, 1997, Pages 463-468

  Gwyther, S ^a   Bolis, G ^b   Gore, M ^c   Ten Bokkel Huinink, W ^d   Verweij, J ^e   Hudson, I R ^f   Despax, R ^g   Jimenez Lacave A ^h  

^a EAST SURREY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f GLAXOSMITHKLINE   (United Kingdom)

^g CLINIQUE PASTEUR   (France)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Independent radiological review; Measurable disease; Objective response rate; Ovarian carcinoma; Standard protocols

Indexed keywords

TOPOTECAN;

ADVANCED CANCER; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 0030798797     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008241127883     Document Type: Article

References (22)

1. Young RC, Ferez CA, Hoskins WJ. Cancer of the ovary. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincott Co. 1993; 1226.
2. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced epithelial ovarian cancer. Ann Intern Med 1989; 111: 273-9.
3. Thigpen T, Blessing J, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynaecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53.
4. Piccart MJ, Gore M, ten Bokkel Huinink W et al. Docetaxel: An active new drug for treatment of advanced ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81.
5. Creemers GJ, Lund B, Verweij J. Topoisomerase 1 inhibitors: Topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
6. Vergote I. Himmelmann A, Frankendal B et al. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47: 282-6.
7. Moore DH, Valea F, Crumpler LS, Fowler WC. Hexamethvlmelamine/altretamine as second-line therapy for epithelial ovarian cancer. Gynecol Oncol 1993; 51: 109-12.
8. Markman M, Hakes T, Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243-8.
9. Baker TR, Piver MS, Hempling RE. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma. Eur J Gynaecol Oncol 1993; XIV: 18-22.
10. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-3.
11. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral eloposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum resistant disease. Br J Cancer 1994; 69: 191-5.
12. R (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat 1994; 33: 39-46.
13. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastalic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
14. Carmichael J. Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
15. Carmichael J, Fink U, Russell RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer, 1996; 73: 101-5.
16. Shepherd FA, Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview. Anti-Cancer Drugs 1995; 6 (Suppl 6): 19-25.
17. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European - Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose venus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
18. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol 1993; 11: 2405- 10.
19. Notice for Guidance on Evaluation of Amicancer Medicinal Products in Man CPMP/205/95, 19 June 1996; Draft Guidelines.
20. Kaye SB, Piccart M, Aapro M, Kavanagh J. Docetaxel in advance ovarian cancer: Preliminary results from three phase II trials. Eur J Cancer 1995; 31A (Suppl 4): S14-S17.
21. Vantongelen K, Steward W, Blackledge G et al. EORTC joint ventures in quality control: Treatment-related variables and data acquisition in chemotherapy trials. Eur J Cancer 1991; 27: 201 -7.
22. Steward WP, Vantongelen K, Verweij J et al. Chemotherapy administration and data collection in an EORTC collaborative group can we trust the results? Eur J Cancer 1993; 29A: 943-7.